Summit Therapeutics Inc.
SMMT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$15.47
KIRA · Stoqly’s AI analyst, in plain words
- Summit Therapeutics Inc. lost $1.1B in fiscal 2025.
- Free cash flow was −$324M in fiscal 2025, — of revenue.
Market cap
$12.0B
P/E
—
Revenue
—
Net income
−$1.1B
Free cash flow
−$324M
Operating margin
—
Summit Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$1.1B
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Summit Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- Summit Therapeutics Inc.
- CIK
- 0001599298
Summit Therapeutics Inc. · SMMT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.8M | $0.7M | $0.0M | $0.0M | — |
| Revenue growth | — | −61.0% | −100.0% | — | — |
| Operating margin | −4,764.3% | −10,225.4% | — | — | — |
| Net income | −$88.6M | −$78.8M | −$615M | −$221M | −$1.1B |
| Net margin | −4,897.8% | −11,174.8% | — | — | — |
| Diluted EPS | −$0.67 | −$0.41 | −$0.99 | −$0.31 | −$1.44 |
| Cash | |||||
| Cash from operations | −$72.6M | −$41.6M | −$76.8M | −$142M | −$323M |
| Capital expenditure | $0.3M | $0.6M | $0.1M | $0.1M | $0.7M |
| Free cash flow | −$72.9M | −$42.2M | −$76.9M | −$142M | −$324M |
| FCF margin | −4,029.5% | −5,986.7% | — | — | — |
| Share count change | — | 46.8% | 220.5% | 16.0% | 4.1% |
| Debt and strength | |||||
| Cash and short-term investments | $71.8M | $349M | $186M | $412M | $713M |
| Shareholders' equity | $83.3M | $127M | $77.7M | $389M | $659M |
| Current ratio | 3.8x | 16.9x | 9.3x | 10.2x | 9.9x |
| Interest coverage | −356.1x | −16.4x | −37.0x | −26.0x | — |
| Returns and quality | |||||
| Return on equity | −108.9% | −75.1% | −601.8% | −94.9% | −206.1% |
| Return on tangible equity | −125.0% | −63.1% | −811.3% | −57.2% | −164.4% |
| Piotroski F-score | — | 3 | 1 | 3 | — |
| Altman Z'' | −6.7 | 3.8 | −30.0 | 1.9 | — |
Insiders bought, 12 months
$104M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Summit Therapeutics Inc. · SMMT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.47 a share, the company is worth $12.0B.
Source: SEC EDGAR XBRL filings (CIK 0001599298). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.